These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 31560165)
1. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165 [TBL] [Abstract][Full Text] [Related]
2. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454 [TBL] [Abstract][Full Text] [Related]
3. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928 [TBL] [Abstract][Full Text] [Related]
4. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553 [TBL] [Abstract][Full Text] [Related]
6. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438 [TBL] [Abstract][Full Text] [Related]
7. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957 [TBL] [Abstract][Full Text] [Related]
8. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668 [TBL] [Abstract][Full Text] [Related]
9. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157 [TBL] [Abstract][Full Text] [Related]
10. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival. January Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765 [TBL] [Abstract][Full Text] [Related]
11. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. Lee CS; Rattu MA; Kim SS J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007 [TBL] [Abstract][Full Text] [Related]
12. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Kim ES; Dhillon S Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231 [TBL] [Abstract][Full Text] [Related]
13. Postibrutinib outcomes in patients with mantle cell lymphoma. Martin P; Maddocks K; Leonard JP; Ruan J; Goy A; Wagner-Johnston N; Rule S; Advani R; Iberri D; Phillips T; Spurgeon S; Kozin E; Noto K; Chen Z; Jurczak W; Auer R; Chmielowska E; Stilgenbauer S; Bloehdorn J; Portell C; Williams ME; Dreyling M; Barr PM; Chen-Kiang S; DiLiberto M; Furman RR; Blum KA Blood; 2016 Mar; 127(12):1559-63. PubMed ID: 26764355 [TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709 [TBL] [Abstract][Full Text] [Related]
15. Novel therapies for relapsed/refractory mantle cell lymphoma. Arora PC; Portell CA Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660 [TBL] [Abstract][Full Text] [Related]